Cargando…
Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber
There is an increasing demand for transdermal transport measurements to optimize topical drug formulations and to achieve proper penetration profile of cosmetic ingredients. Reflecting ethical concerns the use of both human and animal tissues is becoming more restricted. Therefore, the focus of derm...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235028/ https://www.ncbi.nlm.nih.gov/pubmed/34202971 http://dx.doi.org/10.3390/pharmaceutics13060910 |
_version_ | 1783714220673597440 |
---|---|
author | Tárnoki-Zách, Júlia Mehes, Elod Varga-Medveczky, Zsófia Isai, Dona Greta Barany, Nandor Bugyik, Edina Revesz, Zsolt Paku, Sándor Erdo, Franciska Czirok, Andras |
author_facet | Tárnoki-Zách, Júlia Mehes, Elod Varga-Medveczky, Zsófia Isai, Dona Greta Barany, Nandor Bugyik, Edina Revesz, Zsolt Paku, Sándor Erdo, Franciska Czirok, Andras |
author_sort | Tárnoki-Zách, Júlia |
collection | PubMed |
description | There is an increasing demand for transdermal transport measurements to optimize topical drug formulations and to achieve proper penetration profile of cosmetic ingredients. Reflecting ethical concerns the use of both human and animal tissues is becoming more restricted. Therefore, the focus of dermal research is shifting towards in vitro assays. In the current proof-of-concept study a three-layer skin equivalent using human HaCaT keratinocytes, an electrospun polycaprolactone mesh and a collagen-I gel was compared to human excised skin samples. We measured the permeability of the samples for 2% caffeine cream using a miniaturized dynamic diffusion cell (“skin-on-a-chip” microfluidic device). Caffeine delivery exhibits similar transport kinetics through the artificial skin and the human tissue: after a rapid rise, a long-lasting high concentration steady state develops. This is markedly distinct from the kinetics measured when using cell-free constructs, where a shorter release was observable. These results imply that both the established skin equivalent and the microfluidic diffusion chamber can serve as a suitable base for further development of more complex tissue substitutes. |
format | Online Article Text |
id | pubmed-8235028 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82350282021-06-27 Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber Tárnoki-Zách, Júlia Mehes, Elod Varga-Medveczky, Zsófia Isai, Dona Greta Barany, Nandor Bugyik, Edina Revesz, Zsolt Paku, Sándor Erdo, Franciska Czirok, Andras Pharmaceutics Article There is an increasing demand for transdermal transport measurements to optimize topical drug formulations and to achieve proper penetration profile of cosmetic ingredients. Reflecting ethical concerns the use of both human and animal tissues is becoming more restricted. Therefore, the focus of dermal research is shifting towards in vitro assays. In the current proof-of-concept study a three-layer skin equivalent using human HaCaT keratinocytes, an electrospun polycaprolactone mesh and a collagen-I gel was compared to human excised skin samples. We measured the permeability of the samples for 2% caffeine cream using a miniaturized dynamic diffusion cell (“skin-on-a-chip” microfluidic device). Caffeine delivery exhibits similar transport kinetics through the artificial skin and the human tissue: after a rapid rise, a long-lasting high concentration steady state develops. This is markedly distinct from the kinetics measured when using cell-free constructs, where a shorter release was observable. These results imply that both the established skin equivalent and the microfluidic diffusion chamber can serve as a suitable base for further development of more complex tissue substitutes. MDPI 2021-06-20 /pmc/articles/PMC8235028/ /pubmed/34202971 http://dx.doi.org/10.3390/pharmaceutics13060910 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tárnoki-Zách, Júlia Mehes, Elod Varga-Medveczky, Zsófia Isai, Dona Greta Barany, Nandor Bugyik, Edina Revesz, Zsolt Paku, Sándor Erdo, Franciska Czirok, Andras Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber |
title | Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber |
title_full | Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber |
title_fullStr | Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber |
title_full_unstemmed | Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber |
title_short | Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber |
title_sort | development and evaluation of a human skin equivalent in a semiautomatic microfluidic diffusion chamber |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235028/ https://www.ncbi.nlm.nih.gov/pubmed/34202971 http://dx.doi.org/10.3390/pharmaceutics13060910 |
work_keys_str_mv | AT tarnokizachjulia developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber AT meheselod developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber AT vargamedveczkyzsofia developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber AT isaidonagreta developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber AT baranynandor developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber AT bugyikedina developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber AT reveszzsolt developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber AT pakusandor developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber AT erdofranciska developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber AT czirokandras developmentandevaluationofahumanskinequivalentinasemiautomaticmicrofluidicdiffusionchamber |